αPlGF: A New Kid on the Antiangiogenesis Block
- 2 November 2007
- journal article
- editorial
- Published by Elsevier BV in Cell
- Vol. 131 (3), 443-445
- https://doi.org/10.1016/j.cell.2007.10.023
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNature Reviews Cancer, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Discovery of vascular permeability factor (VPF)Experimental Cell Research, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1Nature Medicine, 2003
- Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1Nature Medicine, 2002
- Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditionsNature Medicine, 2001
- Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.Proceedings of the National Academy of Sciences of the United States of America, 1991